Asthma affects an estimated 9.1% of U.S. children \< 18 years of age ([@r1]). Disproportionately high levels of asthma morbidity and mortality are seen in low-socioeconomic and minority populations ([@r2]), with an asthma mortality rate seven times higher among black children than white children ([@r1]). Although little is known about the factors that lead to the development of asthma, researchers have identified a broad range of triggers that are associated with asthma symptoms and exacerbation. These factors include exposure to high levels of indoor allergens, irritants, and mold ([@r11]; [@r12]; [@r19]; [@r20]) and high levels of indoor and outdoor pollutants ([@r12]; [@r14]; [@r18]). Barriers to quality health care and poor continuity of health care are associated with increased asthma morbidity and are especially common in lower-income urban areas ([@r5]; [@r6]). Evidence-based interventions that support the reduction of environmental exposures and facilitate access to care and asthma self-management may address these issues in vulnerable populations.

Even before Hurricane Katrina, Louisiana and the City of New Orleans and surrounding parishes (NOLA) had some of the highest rates of asthma prevalence in the nation ([@r1]; [@r16]). Given the environmental impact of Hurricane Katrina in August 2005, one might expect that children with asthma would be at increased risk. To address the multidimensional nature of the problems in post-Katrina NOLA, the National Institute of Environmental Health Sciences (Research Triangle Park, NC), the National Center on Minority Health and Health Disparities (Bethesda, MD), and the Merck Childhood Asthma Network, Inc. (Washington, DC), came together under the auspices of the Foundation for the National Institutes of Health (NIH; Bethesda, MD) to support an asthma initiative in post-Katrina NOLA.

This initiative, Head-off Environmental Asthma in Louisiana (HEAL), sought to reduce asthma morbidity in children with asthma by employing a combination of evidence-based interventions shown to be efficacious in randomized, controlled clinical trials ([@r7]; [@r15]). These interventions were developed over the past decade as part of the National Cooperative Inner City Asthma (NCICAS) and Inner-City Asthma (ICAS) Studies. These two studies provided patient-tailored counseling in the clinic and home to supply the caretakers of children with asthma with knowledge, skills, and motivation to manage their childen's asthma and reduce exposures to allergens in the home environment. HEAL adapted components of these two evidence-based interventions into a novel, field-applicable, hybrid asthma counselor and environmental intervention to provide support for families with asthma in the aftermath of Hurricane Katrina. In this report we present the results of our effort to translate knowledge from randomized clinical trials to a real-world setting amid unprecedented challenges resulting from a major natural disaster.

Methods
=======

*Study design and population.* HEAL was an observational, pre--post intervention study that recruited NOLA children 4--12 years of age with moderate-to-severe persistent asthma, as defined by the National Asthma Education and Prevention Program (National Heart, Lung, and Blood Institute 2007), over 1 year. The major goal was to determine whether a novel combination of the evidence-based NCICAS asthma counselor and ICAS environmental interventions could be effective in a post-disaster setting ([@r7]; [@r15]). Another goal of HEAL (not covered in this report) was to characterize relationships between environmental exposures and childhood asthma morbidity.

Details regarding the study design, eligibility requirements, recruitment methods, and characteristics of the HEAL study population are provided in the accompanying article ([@r3]). In brief, HEAL was initially designed as a randomized, interventional trial in which 225 children would receive an excellent standard of care, and another 225 would receive the same excellent standard of care plus the intervention. Due to a low recruitment rate, HEAL was transitioned into an observational design in which all enrolled children became eligible for the intervention, including those already randomized to the control group. Although randomized control and intervention groups could not be compared, we were able to compare asthma symptoms among children who saw an asthma counselor earlier in the study versus those who had not. HEAL was approved by the NIEHS, Tulane University, and Louisiana State University institutional review boards; caretakers were asked for written informed consent, and children were asked for written (≥ 7 years of age) or oral (\< 7 years of age) assent, depending on age.

*Intervention.* The HEAL asthma counselors worked in teams with community health workers. The asthma counselors had master's degrees in health-related fields, public health backgrounds, and experience with counseling and community outreach. All had prior experience working with individuals with a chronic disease. The community health workers worked closely with the asthma counselors and helped with several aspects of the study, including building rapport with the caretakers and scheduling visits.

The HEAL intervention was modeled after the intervention used in NCICAS ([@r7]) in which the asthma counselor helped the caretaker to communicate with the child's school nurse, primary care provider, and others involved in caring for the child to develop and implement an asthma action plan individualized to the child. The intervention was tailored to each participant's allergen sensitivities and environmental exposures. In addition, participant-tailored interventions addressed potential problems related to adherence to medication use as well as potential problems with insurance, access to care, and health care attitudes, as identified by risk assessment tools ([@r4]; [@r7]) and prioritized by the asthma counselor. The HEAL intervention also included a participant-tailored environmental component modeled after ICAS ([@r15]). Specifically, the HEAL asthma counselor guided the caretaker in the use of materials provided in an environmental kit (e.g., HEPA air cleaner, wet and dry mops, mattress and pillow encasements, cleaning supplies, food storage containers). The goal of the environmental component was to provide the caretaker with the knowledge, skills, motivation, and supplies to reduce the child's exposure to the allergens to which they were sensitive.

At least two in-person asthma counselor visits were attempted with each caretaker during the intervention year, one in a study office located in a community facility (such as a clinic, library, or school), and the second at the caretaker's home. The asthma counselor followed each visit with a phone call within 2 weeks.

*Study visits.* At baseline, participants completed a clinical evaluation, including an assessment of symptoms, blood collection, and allergen skin testing ([@r3]). In addition, trained clinic staff conducted interviews and filled out the study questionnaires during baseline clinic visits. A baseline home evaluation was conducted 1--27 weeks (median, 3 weeks) after the baseline clinical evaluation; repeat baseline home evaluations were conducted for 14 participants who moved in the first 11 months of the study. Briefly, this evaluation included a visual inspection of the home, air and dust sample collection for mold and allergens, and measurements of indoor air temperature, humidity, and moisture, as described in detail in the accompanying article ([@r10]). Upon completion of both the baseline clinical and home evaluations, children were assigned an asthma counselor. Participants in the control group under the original study design were assigned an asthma counselor when the study was changed from randomized to observational. Clinical evaluations were repeated at month 12, and additional home evaluations were targeted for months 6 and 12. Trained nursing personnel interviewed caretakers by telephone 3, 6, 9, and 12 months after enrollment to obtain information on symptoms, health care utilization, and medication use.

*Statistical methods*. Consistent with the NCICAS and ICAS studies, the primary outcome in HEAL was the maximum symptom days (MSDs) in the previous 2 weeks, which was the largest value among three asthma symptom variables: *a*) the number of days with wheezing, tightness in the chest, or cough; *b*) the number of nights with disturbed sleep as a result of asthma; and *c*) the number of days the child had to slow down or discontinue play activities because of asthma. Asthma symptoms were assessed up to five times during the HEAL project (at baseline and at 3, 6, 9, and 12 months).

Four approaches were taken to evaluate the impact of the intervention. First, we compared mean symptom levels at baseline and after 12 months in the HEAL study population to means from the ICAS and NCICAS intervention groups. Baseline to 12-month changes were tested for each study using *t*-tests. Second, we compared the change in MSDs for HEAL participants based on the timing of the first contact with an asthma counselor using a *t*-test. Third, we conducted an ANCOVA (analysis of covariance) with adjustment for baseline MSD levels comparing MSDs among children who saw an asthma counselor by either 6 or 12 months with symptoms among children who did not, regardless of their randomization status. We conducted similar analyses for several secondary outcomes in HEAL (medication usage and airborne mold, IgE, and allergen levels). For context, we also calculated intervention effects for MSDs at comparable time points in ICAS and NCICAS, which are adjusted for site along with baseline MSD, to improve consistency with the previous manuscripts. Fourth, we investigated differences in the results in HEAL according to baseline characteristics, such as mold exposure, atopy, and IgE, using mixed models with interaction terms between intervention status (based on timing of asthma counselor contact) and each baseline characteristic. Models were adjusted for baseline MSD levels.

Six-month results are presented along with 12-month results when possible, and analyses showing full results at 6 months are included as supplemental tables \[see [Supplemental Material](#ehp-1104242-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1104242>)\]. Participants with missing data are excluded, resulting in 153 and 159 participants in the 6- and 12-month analyses, respectively; as a result, baseline values may differ slightly from previous reports using the full 182-participant study population at baseline.

Results
=======

Baseline demographic and environmental characteristics of the 182 HEAL children have been described in detail elsewhere ([@r3]; [@r10]). In short, HEAL children were mostly African American (67%), and 51% were from households making \< \$30,000 per year. Most HEAL participants (62%) had water damage to their homes as a result of Katrina, with 24% reporting flooding, 25% reporting roof damage, and 14% reporting both flooding and roof damage, compared with 38% who reported no damage. HEAL children had an average of 1.9 in-person meetings with asthma counselors over the course of the study (range, 0--4 visits), with 123 of 182 (68%) children having two or more contacts (in-person visits and asthma counselor telephone calls).

Children in HEAL showed a marked decrease in symptoms over the course of the study, from 6.47 days during the 2 weeks before enrollment to 3.55 days at the 12-month symptom assessment \[*n* = 159 participants who completed 12-month symptom phone call, --2.92 days; 95% confidence interval (CI): --3.92, --1.26, representing a 45% reduction, *p* \< 0.001\]. The magnitude of the change was comparable to changes observed in the MSDs in the ICAS and NCICAS intervention groups, which had reductions of 62% (from 6.00 to 2.31 MSDs, or --3.69 days; 95% CI: --4.28, --3.10) and 35% (5.18 to 3.38 MSDs, or --1.80 days; 95% CI: --2.35, --1.26), respectively (both *p* \< 0.001) ([Figure 1](#f1){ref-type="fig"}).

![MSDs during the previous 2 weeks at baseline (blue) and 12 months (gray) for HEAL (all participants), ICAS, and NCICAS participants who received the study intervention. Changes in MSDs are shown with 95% CIs and p-values comparing symptoms at baseline and 12 months.](ehp.1104242.g001){#f1}

Of the 153 HEAL children who had a 6-month symptom assessment call, 80 (53%) had seen an asthma counselor before the call ([Figure 2](#f2){ref-type="fig"}). By the 12-month call, 87% of the children had met with their asthma counselor (139 of 159). Baseline asthma symptoms (i.e., MSDs, pulmonary function, and controller medication) were similar between children who had seen a counselor before the 12-month assessment and those who had not (*n* = 20), but there were significant differences between the groups in demographic characteristics (63% vs. 95% from Orleans Parish, 63% vs. 85% African American), environmental exposures (3,281 vs. 8,408 outdoor mold spores/m^3^), and season of enrollment (36% vs. 95% enrolled in the spring or summer of 2007) ([Table 1](#t1){ref-type="table"}). Similar patterns of differences in baseline characteristics were observed between children who had asthma counselor contact before versus after 6 months \[see Supplemental Material, [Table S1](#ehp-1104242-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1104242>)\].

![The timings of the participants' first contacts with an asthma counselor in HEAL are shown. Although all HEAL participants were eligible for the intervention, some did not see an asthma counselor until later in the study. Values exclude participants who missed the given assessment (month 6: 29/182; month 12: 23/182). Shaded gray bars represent the interquartile range for the timing of the 6- and 12-month symptom assessment excluding participants who missed the visits.](ehp.1104242.g002){#f2}

###### 

Baseline characteristics by timing of the first contact with an asthma counselor.

  Characteristic                                                                                                                                                                                  Contact with asthma counselor before 12 months   *p*-Value       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ --------------- ------
  Symptoms                                                                                                                                                                                        6.6 ± 5.0                                        5.8 ± 3.9       0.48
  Parish                                                                                                                                                                                          0.004                                                            
  Orleans                                                                                                                                                                                         88/139 (63%)                                     19/20 (95%)     
  Jeffersona                                                                                                                                                                                      51/139 (37%)                                     1/20 (5%)       
  Enrollment season                                                                                                                                                                               \< 0.001                                                         
  Spring 2007                                                                                                                                                                                     14/139 (10%)                                     15/20 (75%)     
  Summer 2007                                                                                                                                                                                     36/139 (26%)                                     4/20 (20%)      
  Fall 2007                                                                                                                                                                                       49/139 (35%)                                     ---             
  Winter 2007                                                                                                                                                                                     32/139 (23%)                                     1/20 (5%)       
  Spring 2008                                                                                                                                                                                     8/139 (6%)                                       ---             
  Race/ethnicity                                                                                                                                                                                  0.03                                                             
  African American                                                                                                                                                                                88/139 (63%)                                     17/20 (85%)     
  Hispanic                                                                                                                                                                                        9/139 (6%)                                       2/20 (10%)      
  Other                                                                                                                                                                                           42/139 (30%)                                     1/20 (5%)       
  Income \< \$15,000                                                                                                                                                                              30/128 (23%)                                     7/19 (37%)      0.26
  Female sex                                                                                                                                                                                      61/139 (44%)                                     12/20 (60%)     0.81
  Lung function                                                                                                                                                                                                                                                    
  FEV1% predicted                                                                                                                                                                                 90.7 ± 17.7                                      98.3 ± 15.1     0.25
  FEV1/FVC                                                                                                                                                                                        77.8 ± 10.5                                      80.0 ± 8.3      0.57
  Taking Inhaled corticosteroids                                                                                                                                                                  81/139 (58%)                                     11/20 (55%)     0.81
  Mold levels (spores/m3)                                                                                                                                                                                                                                          
  Outdoor total                                                                                                                                                                                   3,281 (445)                                      8,408 (2,299)   0.01
  Indoor total                                                                                                                                                                                    480 (52)                                         675 (237)       0.28
  IgE (serum)                                                                                                                                                                                                                                                      
  Total IgE (kU/L)                                                                                                                                                                                130 (38)                                         240 (32)        0.10
  Positive mold-specific IgE                                                                                                                                                                      74/133 (56%)                                     7/19 (37%)      0.63
  Exposure to allergens in dust                                                                                                                                                                                                                                    
  Alternaria \> 10 µg/g                                                                                                                                                                           86/138 (62%)                                     7/20 (35%)      0.03
  Detectable roach                                                                                                                                                                                30/138 (22%)                                     3/20 (15%)      0.77
  Detectable dust mite                                                                                                                                                                            54/138 (39%)                                     5/20 (25%)      0.32
  Detectable mouse                                                                                                                                                                                84/138 (61%)                                     12/20 (60%)     0.99
  Skin test result                                                                                                                                                                                                                                                 
  Alternaria                                                                                                                                                                                      72/138 (52%)                                     11/20 (55%)     0.99
  Roach                                                                                                                                                                                           69/138 (50%)                                     12/20 (60%)     0.48
  Dust mite                                                                                                                                                                                       89/138 (64%)                                     16/20 (80%)     0.21
  Mouse                                                                                                                                                                                           39/138 (28%)                                     5/20 (25%)      0.99
  Abbreviations: FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity. Values are n (%), mean ± SD, or geometric mean (geometric SD). aAlso includes St.Tammany and St. Bernard.                                                                    

At the 6-month symptom phone call, the 80 children who had seen an asthma counselor had a 4.09-MSD reduction from baseline, compared with a 1.79-day decrease for the 73 children who had not yet seen an asthma counselor (--2.31 days; 95% CI: --3.53, --1.08; *p* \< 0.001). At 12 months, the group that had seen a counselor had a 3.14-day improvement compared with a 1.29-day improvement for those who had not (--1.85 days; 95% CI: --3.74, 0.04; *p* = 0.06). The effect sizes seen in ICAS and NCICAS were somewhat smaller but showed greater statistical significance because the studies included more children and had a more powerful study design (i.e., randomized, controlled trial) than did HEAL. In ICAS, there was a 0.66-day intervention effect at 6 months and a 0.84-day effect at 1 year (both *p* \< 0.01); similar effects were seen in NCICAS (0.65- and 0.76-day effects at 6 and 12 months, respectively, both *p* \< 0.01) ([Figure 3](#f3){ref-type="fig"}).

![Change in MSDs between baseline and the 6-month assessment (*A*) and between baseline and the 12-month assessment (*B*) in HEAL, ICAS, and NCICAS. ICAS and NCICAS participants are grouped by their treatment intervention (Int) or control (Ctl) randomization assignment, and HEAL participants are grouped by whether they had contact with an asthma counselor before the given assessment (Ctl: no intervention before assessment; Int: received intervention before assessment). Values are effect sizes (95% CIs) and p-values. ICAS and NCICAS estimates are adjusted for site.](ehp.1104242.g003){#f3}

Children who saw an asthma counselor in the first 6 months of the study had decreased symptoms relative to baseline (4.14 days decrease at month 6 among the 77 participants who completed all symptom assessments). These same children had significantly less asthma counselor contact in the second half of the study (0.6 average contacts compared with 1.6 in the first 6 months, *p \<* 0.001), with a corresponding partial rebound for symptom level (1.17-day increase from 6 to 12 months, *p* = 0.07, [Table 2](#t2){ref-type="table"}). Children who saw an asthma counselor for the first time after 6 months of the study also showed a statistically significant decrease in symptoms in the first 6 months (1.88-day decrease for 52 participants, *p* = 0.04); however, this decrease in symptoms was more modest when compared with participants who had already seen an asthma counselor in the first 6 months (*p* = 0.02). Also, the children who did not see an asthma counselor until after the first 6 months saw their counselors an average of 1.8 times each during the second 6 months and saw a corresponding larger symptom improvement (1.13-day decrease vs. 1.17-day increase for participants who first saw an asthma counselor in the first 6 months, *p* = 0.01).

###### 

Changes in MSDs during the previous 2 weeks by timing of the first contact with an asthma counselor.

  First asthma counselor contact                                                                                                                                                                                                                                                                                                                                                                                                            n^a^   Symptoms by month   Change in symptoms                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------ ------------------- -------------------- ------ -------------------------- ------------------------ --------------------- ------
  Before 6 months                                                                                                                                                                                                                                                                                                                                                                                                                           77     6.52                2.38                 3.55   --4.14 (--5.50, --2.79)d   0.02                     1.17 (--0.10, 2.43)   0.01
  After 6 months                                                                                                                                                                                                                                                                                                                                                                                                                            52     5.83                3.94                 2.81   --1.88 (--3.71, --0.06)    --1.13 (--2.67, 0.40)d                         
  aThe 41 participants with missing symptom assessments and 20 participants who never saw an asthma counselor are excluded. bChange in MSD between symptom assessments at baseline and 6 months (Change 0→6) and 6 months and 12 months (Change 6→12) with 95% CIs. cTests for a difference (p-diff) in change over time by timing of the first asthma counseling contact. dMeasures corresponding to the first asthma counselor contact.                                                                                                                                    

Levels of mold exposure in HEAL showed marked decreases between the baseline and 12-month home evaluations. The bedroom airborne mold exposure dropped from 522 to 266 spores/m^3^, and the *Alternaria* levels in bedroom dust dropped from 11.6 to 6.0 μg/g (both *p* \< 0.001). However, it is not possible to determine if the intervention played a role in these decreases. Although children who saw an asthma counselor before 12 months had lower levels of IgE, dust-based allergen exposure, and indoor airborne mold exposure at 12 months than children who had not seen a counselor, data were available for only 15 children in the latter group, and none of the differences reached statistical significance (all *p* \> 0.25) ([Table 3](#t3){ref-type="table"}). Participants who had seen an asthma counselor in the first 6 months also showed nominally improved environmental conditions for most outcomes (airborne mold; dust-based roach, mite, and *Alternaria*) at the 6-month home evaluation visit when compared with those who had not seen an asthma counselor in that time frame \[all *p* \> 0.15; see also Supplemental Material, [Table S2](#ehp-1104242-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1104242>)\]. The only exception was the level of mouse allergen, which was 18 percentage points higher for the participants with asthma counselor contact (*p* = 0.06).

###### 

Symptoms at 12 months, exposures, and allergic characteristics by timing of the first contact with an asthma counselor.

  Contact with asthma counselor before 12 months                              *p*-Value                                                 
  --------------------------------------------------------------------------- ----------- --------------- ---- --------------- -------- ------
  Maximum symptom days                                                        139         3.32 ± 0.3      20   5.17 ± 0.9      --1.85   0.05
  Taking medication (%)                                                       121         68.3 ± 4.6      16   43.7 ± 13.6     24.6     0.09
  Mold levels (spores/m3)                                                                                                               
  Outdoor total                                                               131         2,576 ± 462.5   15   1,364 ± 731.8   1,212    0.26
  Indoor total                                                                131         258 ± 27.4      15   356 ± 112.1     --98     0.34
  IgE (serum)                                                                                                                           
  Total (kU/L)                                                                111         274 ± 16.6      15   284 ± 47.4      --10     0.84
  Detectable mold IgE (%)                                                     112         44.4 ± 11.5     15   62.7 ± 24.3     --18.3   0.51
  Allergens in dust (%)                                                                                                                 
  Alternaria \> 10 µg/g                                                       126         29.9 ± 4.2      15   44.3 ± 13.4     --14.4   0.29
  Detectable roach                                                            126         31.9 ± 4.2      15   27.8 ± 11.9     4.1      0.76
  Detectable dust mite                                                        126         35.6 ± 4.4      15   49.3 ± 13.3     --13.7   0.32
  Detectable mouse                                                            126         53.3 ± 4.6      15   67.9 ± 12.4     --14.6   0.31
  Values in each row are adjusted for baseline levels of the given outcome.                                                             

In addition to reductions in asthma symptoms, children who saw an asthma counselor before 12 months were also more likely to be taking inhaled corticosteroids (ICS) at the end of the study (68.3% compared with 43.7%, *p* = 0.09) ([Table 3](#t3){ref-type="table"}). We found that associations between asthma counselor contact and MSD were generally the same regardless of baseline participant characteristics. Although participants taking ICS at baseline did see larger MSD decreases if they had asthma counselor contact at 12 months (3.51-day decrease vs. 0.20-day increase for those not taking ICS, *p* = 0.055), sample size was generally inadequate for this type of comparison and other baseline characteristics (airborne mold, IgE, and dust allergen levels) showed no relationship ([Table 4](#t4){ref-type="table"}). The 6-month findings were similar, with only parish being a significant predictor of increased response by 6 months \[3.00-day decrease in Orleans compared with 0.21-day decrease in other parishes, *p* = 0.04; see also Supplemental Material, [Table S3](#ehp-1104242-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1104242>)\].

###### 

Differences in MSDs according to intervention status at 12 months and baseline characteristics.

  Baseline status                  Contact with asthma counselor before 12 months                                        
  -------------------------------- ------------------------------------------------ ------ ----- ------ -------- ------- ------
  Parish                                                                                                                 
  Jefferson                        1                                                5.08   51    3.12   --1.97   0.630   0.96
  Orleans                          19                                               5.18   88    3.44   --1.74   0.089   
  Taking inhaled corticosteroids                                                                                         
  No                               9                                                3.20   58    3.40   0.20     0.890   0.05
  Yes                              11                                               6.78   81    3.27   --3.51   0.007   
  Outdoor mold                                                                                                           
  \< 1,000 spores/m3               1                                                5.45   31    3.57   --1.88   0.647   0.99
  ≥ 1,000 spores/m3                19                                               5.16   108   3.25   --1.91   0.059   
  Bedroom mold                                                                                                           
  \< 1,000 spores/m3               11                                               5.78   105   3.26   --2.52   0.049   0.42
  ≥ 1,000 spores/m3                9                                                4.43   34    3.51   --0.92   0.544   
  Total IgE                                                                                                              
  \< 100 kU/L                      5                                                7.61   36    3.29   --4.32   0.026   0.17
  ≥ 100 kU/L                       14                                               4.60   95    3.37   --1.23   0.285   
  Detectable mold IgE                                                                                                    
  No                               12                                               6.36   74    3.38   --2.98   0.018   0.22
  Yes                              7                                                3.70   59    3.23   --0.46   0.771   
  Alternaria                                                                                                             
  \< 10 µg/g                       13                                               5.92   52    3.56   --2.36   0.060   0.38
  ≥ 10 µg/g                        7                                                3.80   86    3.21   --0.59   0.710   
  Detectable roach                                                                                                       
  No                               17                                               5.60   108   3.41   --2.19   0.039   0.35
  Yes                              3                                                2.82   30    3.11   0.29     0.906   
  Detectable dust mite                                                                                                   
  Yes                              15                                               5.50   84    3.37   --2.13   0.062   0.58
  No                               5                                                4.20   54    3.30   --0.90   0.638   
  Detectable mouse                                                                                                       
  Yes                              8                                                5.69   54    2.54   --3.14   0.039   0.27
  No                               12                                               4.83   84    3.86   --0.97   0.431   

Discussion
==========

Translating evidence-based interventions to real-world settings is difficult under the best of circumstances. We had anticipated that this would be an extraordinary challenge in the aftermath of Hurricane Katrina, one of the United States' most devastating disasters. However, given the substantial needs of the families and children with asthma in this community, which already had one of the highest asthma rates in the country, we felt this effort was critically important.

This study demonstrates that evidence-based asthma counselor and environmental interventions to improve asthma management and reduce environmental exposures can be combined and effectively implemented in a post-disaster setting. The application of this novel combination of the ICAS and NCICAS interventions was associated with a decrease in asthma symptoms that was consistent with differences observed in intervention versus non-intervention groups in these earlier, tightly controlled NIH studies.

In the NCICAS intervention, asthma counselors helped the caretakers to manage their child's asthma and emphasized the importance of proper medication use and avoidance of environmental triggers, although no home visits or direct demonstrations of environmental risk factor mitigation were undertaken ([@r7]). The asthma counselors in NCICAS began their interventions with two group asthma counseling sessions, followed by in-clinic visits every other month and telephone calls on the alternate months over the course of a year, for a total of 6 clinic visits and 6 calls. The ICAS environmental intervention did not provide asthma counseling nor did it involve the primary care physicians, but rather had environmental mitigation staff provided remediation of identified environmental risks (based on the child's sensitivity and exposure) and discussed ways to change behavior to reduce or eliminate those risks during the course of 4--7 home visits for each family ([@r15]).

These NIH-funded interventions (NCICAS and ICAS) were quite different in nature, and both were effective but very demanding on the staff and the families. In consideration of the many demands and difficulties being encountered by the post-Katrina NOLA population, the maximum number of contacts with HEAL participants was reduced to two in-person visits (one of which took place in the home) and up to two follow-up telephone contacts. However, even though considerably fewer home visits than ICAS and fewer asthma counselor contacts than NCICAS occurred in HEAL, HEAL appeared to be similarly effective. This outcome suggests that the use of asthma counselors who are well trained in asthma counseling and home environmental interventions is applicable to the community setting and that similar strategies might be useful in other resource-limited or post-disaster settings to improve the health of children with respiratory and other health conditions.

In the uncontrolled settings of translational and observational studies, limitations must be considered when interpreting the findings. There were differences in demographics, environment, and season of enrollment between those who saw an asthma counselor before the 12-month symptom assessment and those who did not. Many of these differences between the groups were a result of limitations imposed by the recruitment constraints that led to modifications in the study design. Children randomized to the non-intervention group before the study redesign and before the recruitment area had been expanded beyond Orleans Parish were more highly represented in the group who had not seen an asthma counselor by 6 or 12 months. In fact, 19 of the 20 children who did not see an asthma counselor before their 12-month symptom call were from Orleans Parish. There were differences between HEAL participants from Orleans Parish versus those from other parishes, which are described elsewhere ([@r3]), and these differences may have influenced associations between the intervention and symptoms in HEAL. Although the intervention showed a trend toward reduced allergen levels, concomitant changes were occurring following Katrina; a natural reduction of mold levels and home renovations and remediation also took place after the storm ([@r10]) and undoubtedly contributed to improvements in asthma symptoms.

The Inner-City Asthma Intervention, which was an earlier implementation of the asthma counselor NCICAS intervention in community settings conducted by the Centers for Disease Control and Prevention, reported challenges similar to some faced in HEAL ([@r13]; [@r21]). In general, there are many considerations when translating clinical trials into clinical practice, which have been well described ([@r8]; [@r9]). Although the HEAL project faced many of these problems as well as the additional challenges presented by the post-Katrina setting, we believe this effort demonstrated the value and effectiveness of translating evidence-based clinical trials into real world settings, even in a community struggling to recover from the most costly and destructive disaster to ever occur in the United States.

Supplemental Material
=====================

###### 

Click here for additional data file.
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